

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-283US

In Re Application Of: MEHTA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,062	23 December 2002	TBA	026815	TBA	

Title:

FLAVAXATE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-283US

In Re Application of: **MEHTA et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,062	23 December 2002	TBA	026815	TBA	

Title:

FLAVAXATE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 _____ as described below.
- Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Signature

Dated: **January 31, 2006**

George E. Heibel, Esq.

Reg. No. 42,648

Ranbaxy Inc.

600 College Road East, Suite 2100

Princeton, NJ 08540

Tel.: (609) 720-5334

Fax: (609) 514-9779

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-283US

Serial No.: 10/540,062

Applicants: M. STA et al.

Filed: 6/22/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	3,176,019	3/30/1965	Campbell et al.	260	293.4	
	A2	5,281,601	1/25/1994	Cross et al.	514	320	
	A3	5,948,792	9/7/1999	Tsuchiya et al.	514	317	
	A4	6,130,232	10/10/2000	Mase et al.	514	318	
	A5	6,174,900	1/16/2001	Okada et al.	514	317	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 072 620	2/23/1983	EPO	C07D	405/12	
	B2	EP 0 108 986	5/23/1984	EPO	C07D	311/30	
	B3	EP 0 267 319	5/18/1988	EPO	C07C	153/11	
	B4	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
	B5	EP 0 388 054	9/19/1990	EPO	C07D	207/08	
	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
	B7	GB 940,540	10/30/1963	UK	C07C		
	B8	JP 135958/1994	5/17/1994	Japan	C07D	333/16	
	B9	JP 92921/1994	4/5/1994	Japan	C07C	237/20	
	B10	WO 91/09013	6/27/1991	PCT	C07D	207/08	
	B11	WO 93/16018	8/19/1993	PCT	C05F	17/02	
	B12	WO 93/16048	8/19/1993	PCT	C07D	211/26	Equivalent CA 2155320
	B13	WO 96/33973	10/31/1996	PCT	C07D	211/46	Equivalent US 5,750,540
	B14	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract
	B15	WO 98/05641	2/12/1998	PCT	C07D	211/46	Equivalent US 5,948,792
	B16	WO 98/29402	7/9/1998	PCT	C07D	311/20	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-283US	Serial No.: 10/540,062
	Applicants: M [REDACTED] TA et al.	
	Filed: 6/22/2005	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)
C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)
C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)
C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)
C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)
C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)
C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)
C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)
C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282
C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)
C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> :984-987 (2002)
C13	Braish et al., "Construction of the (1 α ,5 α ,6 α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", <i>Synlett</i> , 1100-1102 (1996)
C14	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
C15	Cheng and Prusoff, "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	